The Multiple Sclerosis Society of Canada has funded Canada’s first stem cell clinical trial to treat multiple sclerosis, conducted by researchers at the University of Ottawa. The trial, called MESCAMS [Mesenchymal Stem Cell Therapy for Canadian MS patients], will comprise MSC infusions to the central nervous system to utilize their ability to regulate autoimmune attacks and reduce inflammation in 40 MS patients. Continue reading
Ophthalmologists James L Funderburgh, Ph.D. and Fatima Syed-Picard, Ph.D. from the University of Pittsburgh have devised a method for treating corneal blindness by utilizing dental pulp stem cells. The researchers harvested the stem cells from molars discarded during routine extraction and induced the cells to differentiate into keratocytes [corneal cells]. They then seeded the cells onto a nanofiber scaffold, allowing them to grow into fully developed, functional corneas capable of restoring eyesight. Continue reading
In a new two year clinical trial conducted by the University of Miami, researchers will attempt to treat deep second degree burn victims with mesenchymal stem cells [MSCs] as a potential alternative to skin grafts. The team, led by Dr. Evangelos Badiavas, will first cover the wounds in protective dressing, and then inject the MSCs under the dressing and into the wounds to spur the regeneration of the inner and outer layers of skin.
Severe burns currently account for 450,000 emergency room treatments annually, as well as 15-20% of combat injuries to military veterans. But despite a high demand to eliminate painful and taxing skin graft surgeries, they are currently the only option for reconstruction. While Dr. Badiavas’ stem cell therapy is in its initial assessment phase, early indications point to possible MSC treatments that may provide a more comfortable and efficient method to regenerate healthy skin tissue, resulting in better outcomes for patients.
As regenerative engineering progresses, we believe the best stem cells to use in emerging treatments will be the patient’s own [autologous stem cells] as this negates the need to find a suitable donor and eliminates the chances of rejection of the transplanted tissue. To learn more about banking your own valuable stem cells to insure your family’s future health, visit StemSave or call 877-783-6728 (877-StemSave) today.
To view the full article, click here.
The Future of Regenerative Medicine is Now™
Researchers from Okayama University have developed a method to treat the congenital heart defect known as hypoplastic left heart syndrome [HLHS] by utilizing a specialized cardiac stem cell. In a Phase I clinical trial conducted on children suffering from HLHS, the scientists concluded that, because the young stem cells in children are more abundant and self-renewing than those in adults, intracoronary injection of stem cells is a safe and feasible approach to treating the condition. Continue reading
According to a recently published study from the Brigham and Woman’s Hospital, mesenchymal stem cells [MSCs] have the ability to reverse type I diabetes by suppressing the auto-immune attack of islet cells. Although the MSCs cannot be directly injected into the pancreas, the researchers utilized the surface adhesion molecule HCELL to hone the stem cells in on the inflamed islets, allowing them to normalize blood sugar levels without the use of insulin. Continue reading
Jackson Laboratory scientists have identified the adult lung stem cells p63+/Krt5+ as the specific cell line that specializes in lung regeneration. In an animal model, professors Frank McKeon, Ph.D. and Wa Xian, Ph.D. observed as the p63+/Krt5+, which typically mature into the lungs’ alveoli, responded to lung damage caused by the H1N1 influenza virus by migrating to the sites of inflammation and restoring the lost tissue. Continue reading
In a recent update of an ongoing five year clinical trial conducted by the Chicago Blood Cancer Institute, patients with relapsing-remitting multiple sclerosis have experienced suppression of disease-related inflammation as a result of hematopoietic stem cell transplantations. The stem cells have the ability to regulate the autoimmune attack on the central nervous system, and have provided 82.8% of the patients with two years thus far of event-free disease remission. Continue reading
New research from McGill University has shown that the bladder acellular matrix [BAM], or the external structure of connective tissue and growth factors that house the cellular components of the bladder, can serve as a scaffolding unit for mesenchymal stem cells [MSCs] to regenerate healthy bladder tissue. The stem cells receive growth factors from the BAM, which direct them to differentiate into new bladder cells that, when transplanted into an animal model, exhibit nearly 100% normal bladder capacity and function. Continue reading
Researchers led by Eduardo Marbón of the Cedars-Sinai Heart Institute have developed a method to prolong the lives of patients with Duchenne Muscular Dystrophy [DMD] through the infusion of cardiac stem cells. The stem cells reverse the loss of cardiac muscle caused by the genetic disease, preventing heart failure that would otherwise limit a patient’s life expectancy to age 25. Continue reading
Medical researchers from Keele University and Nottingham University have integrated remote controlled magnetic nanoparticles to incite the differentiation of stem cells into new bone tissue for the treatment of bone diseases, disorders, and injuries. In pre-clinical trials, the nanoparticles were coated with proteins that stimulate the stem cells, and then delivered directly to the damaged tissue via an external magnetic field. Continue reading